G1 Therapeutics, Inc.
G1 Therapeutics, Inc. (GTHX) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · GTHX · as of Jun 9, 2026
Activity summary
Buy transactions
0
P-Purchase only
Sell transactions
34
12 Months
Buy/Sell ratio
0.00
Buy/Sell (by trades)
Overall sentiment
G1 Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
GTHX insider buying and selling by quarter
GTHX insider selling · GTHX insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Recent insider transactions
GTHX executive sell shares · GTHX board member insider trading · GTHX insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Sep 18, 2024 | Secor Alicia Director | Other | 20,000 | $143K | Form 4 |
| Sep 18, 2024 | Secor Alicia Director | Other | 10,000 | — | Form 4 |
| Sep 18, 2024 | Thomas Monica R. Chief Legal & People Officer | Other | 138,151 | $988K | Form 4 |
| Sep 18, 2024 | Thomas Monica R. Chief Legal & People Officer | Other | 6,674 | — | Form 4 |
| Sep 18, 2024 | Flowers Cynthia Louise Director | Other | 20,000 | $143K | Form 4 |
| Sep 18, 2024 | Flowers Cynthia Louise Director | Other | 15,889 | — | Form 4 |
| Sep 18, 2024 | Nicholson Garry A Director | Other | 20,000 | $143K | Form 4 |
| Sep 18, 2024 | Lee Jacks Director | Other | 10,000 | $72K | Form 4 |
| Sep 18, 2024 | Nicholson Garry A Director | Other | 14,389 | — | Form 4 |
| Sep 18, 2024 | Lee Jacks Director | Other | 10,000 | — | Form 4 |
| Sep 18, 2024 | Bailey John E. (Jack) Jr. President and CEO · Director | Award | 181,400 | — | Form 4 |
| Sep 18, 2024 | Bailey John E. (Jack) Jr. President and CEO · Director | Other | 534,787 | $3.82M⚡ | Form 4 |
| Sep 18, 2024 | Umstead John W. V CFO | Other | 168,387 | $1.20M⚡ | Form 4 |
| Sep 18, 2024 | Bailey John E. (Jack) Jr. President and CEO · Director | Other | 196,287 | — | Form 4 |
| Sep 18, 2024 | Umstead John W. V CFO | Other | 19,331 | — | Form 4 |
| Sep 18, 2024 | Malik Rajesh Chief Medical Officer | Award | 17,900 | — | Form 4 |
| Sep 18, 2024 | Malik Rajesh Chief Medical Officer | Other | 89,762 | $642K | Form 4 |
| Sep 18, 2024 | Malik Rajesh Chief Medical Officer | Other | 87,450 | — | Form 4 |
| Sep 18, 2024 | Avagliano Mark Chief Business Officer | Award | 20,600 | — | Form 4 |
| Sep 18, 2024 | Avagliano Mark Chief Business Officer | Other | 236,610 | $1.69M⚡ | Form 4 |
| Sep 18, 2024 | Avagliano Mark Chief Business Officer | Other | 26,035 | — | Form 4 |
| Sep 18, 2024 | Sharpless Norman Director | Other | 20,000 | $143K | Form 4 |
| Sep 18, 2024 | MURDOCK TERRY L COO | Award | 17,900 | — | Form 4 |
| Sep 18, 2024 | MURDOCK TERRY L COO | Other | 124,762 | $892K | Form 4 |
| Sep 18, 2024 | MURDOCK TERRY L COO | Other | 21,150 | — | Form 4 |
Thomas Monica R.
Chief Legal & People Officer
Date
Sep 18
Shares
138,151
Price
$7.15
Value
$988K
Thomas Monica R.
Chief Legal & People Officer
Date
Sep 18
Shares
6,674
Price
—
Value
—
Bailey John E. (Jack) Jr.
President and CEO · Director
Date
Sep 18
Shares
181,400
Price
—
Value
—
Bailey John E. (Jack) Jr.
President and CEO · Director
Date
Sep 18
Shares
534,787
Price
$7.15
Value
$3.82M ⚡
Bailey John E. (Jack) Jr.
President and CEO · Director
Date
Sep 18
Shares
196,287
Price
—
Value
—
Malik Rajesh
Chief Medical Officer
Date
Sep 18
Shares
89,762
Price
$7.15
Value
$642K
Avagliano Mark
Chief Business Officer
Date
Sep 18
Shares
236,610
Price
$7.15
Value
$1.69M ⚡
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About GTHX insider trading
GTHX insider trades
G1 Therapeutics, Inc. (GTHX) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including GTHX. Over the past 12 months, 0 insiders have filed transactions with the SEC. GTHX insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For G1 Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
GTHX insider trading · 5 questionsThe insiders of G1 Therapeutics, Inc. (GTHX) include executives and directors such as GTHX, among others. Over the past 12 months, 0 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026